Research discoveries made at MD Anderson are leading to improved therapies for cancer patients.
Here are some recent advances. Select any headline to read more about that topic.
Seeing children endure chronic pain associated with cancer treatment inspired Howard Gutstein, M.D., and his colleagues to focus their research on pain management. They found that the cellular process that causes morphine tolerance can be blocked by a reformulated form of imatinib.
As early as 1867, doctors noticed that cancer patients are at high risk for developing blood clots. Recently, MD Anderson professor Anil Sood, M.D., and colleagues discovered an explanation and a vicious cycle.
By combining two drugs, researchers shrank tumors in some patients with treatment-resistant Ewing’s sarcoma, a cancer that primarily affects the bones and most often occurs in teens and young adults.
Four proteins have been linked to poor prognosis for certain types of breast cancer and could lead to targeted therapies, according to MD Anderson researchers.
Unerstanding the "what" and "how" of telomeres and telomerase may be critical in treating and eliminating cancer.
An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients who participated in an international Phase I clinical trial.
A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting.